Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...